# US 2015/0105545 A1 · Interfering rna molecules

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105545 A1
- Document ID: US20150105545A1
- Status: Published application
- Kind: A1
- Application number: 14/578,636
- Filed: 2014-12-22
- Published: 2015-04-16
- Earliest claimed: 2002-08-05
- Assignees: Silence Therapeutics GmbH
- Applicants: Silence Therapeutics Aktiengesellschaft (AG)
- Inventors: KLAUS GIESE; JÖRG KAUFMANN; ANKE KLIPPEL-GIESE
- Web page: https://patentgrep.com/patent/US20150105545A1

## CPC

- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 13/08: of the prostate
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 5/10: Cells modified by introduction of foreign genetic material
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12Q 1/68: involving nucleic acids
- C12Y 207/11001: Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
- C12Y 301/03048: Protein-tyrosine-phosphatase (3.1.3.48)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2310/13: Decoys
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/317: with an inverted bond, e.g. a cap structure
- C12N 2310/3183: Diol linkers, e.g. glycols or propanediols
- C12N 2310/32: of the sugar
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/322: 2'-R Modification
- C12N 2310/332: Abasic residue
- C12N 2310/343: having patterns, e.g. ==--==--==--
- C12N 2310/346: having a combination of backbone and sugar modifications
- C12N 2310/3521: Methyl
- C12N 2310/3525: MOE, methoxyethoxy
- C12N 2310/53: partially self-complementary or closed
- C12N 2310/531: Stem-loop; Hairpin
- C12N 2320/50: Methods for regulating/modulating their activity
- C12N 2320/51: modulating the chemical stability, e.g. nuclease-resistance
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Y: ENZYMES

## Abstract

The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.

## Claims

### Claim 1

(canceled)

### Claim 2

A ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides and whereby said second stretch is at least partially identical to a target nucleic acid, whereby the double stranded structure is blunt ended or has an overhang and a plurality of the ribonucleic acids on the first or second stretch/strand has a modification at the 2′-position and the modification is selected from an amino, fluoro, methoxy, alkoxy or alkyl modification.

### Claim 3 (depends on 2)

The ribonucleic acid according to claim 2, wherein the 2′ modification is selected from 2′-O-methyl and 2′-Fluoro.

### Claim 4 (depends on 2)

The ribonucleic acid according to claim 2, wherein the double stranded structure is blunt ended on the double stranded structure which is defined by the 3′-end of the first strand and the 5′-end of the second strand.

### Claim 5

The ribonucleic acid according to claim wherein at least one of the strands has an overhang of at least one nucleotide at the 3′-end consisting of ribonucleotide or deoxyribonucleotide.

### Claim 6 (depends on 2)

The ribonucleic acid according to claim 2, wherein the double stranded structure has a length of 17 to 21 nucleotides.

### Claim 7 (depends on 2)

The ribonucleic acid according to claim 2, wherein the ribonucleic acid has an overhang at the 3′-end of the second strand.

### Claim 8 (depends on 2)

The ribonucleic acid according to claim 2, wherein said ribonucleic acid has a double stranded structure that is 15 to 23 nucleotides in length.
